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Abstract
Primary human cytomegalovirus (HCMV) infections during pregnancy are associated with a high risk of virus transmission to
the fetus. To identify correlates of intrauterine HCMV transmission, serial serum samples from HCMV transmitter and non-
transmitter pregnant women with primary HCMV infection were analyzed for the presence of neutralizing antibodies
against different glycoproteins and glycoprotein complexes, which are known to mediate entry into distinct types of host
cells. Neutralizing activity was detected in the sera early after primary infection; absorption with a soluble pentameric
complex formed by gH/gL/pUL128-131, but not with gH/gL dimer or with gB, abolished the capacity of sera to neutralize
infection of epithelial cells. Importantly, an early, high antibody response to pentamer antigenic sites was associated with
a significantly reduced risk of HCMV transmission to the fetus. This association is consistent with the high in vitro inhibition
of HCMV infection of epithelial/endothelial cells as well as cell-to-cell spreading and virus transfer to leukocytes by anti-
pentamer antibodies. Taken together, these findings indicate that the HCMV pentamer complex is a major target of the
antibody-mediated maternal immunity.
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Introduction
Human cytomegalovirus (HCMV) is the most common cause
of congenital infection, leading to sensorineural hearing loss and
neurodevelopmental delay [1]. The birth prevalence of congen-
ital HCMV infection is estimated to be 0.6–0.7%, with a 11–
13% symptomatic newborns rate at birth [2,3]. The rate of
transmission in utero is much higher (32.3% vs 1.4%) for primary
versus non-primary infections [2]. In a recent study on 735
pregnancies complicated by primary HCMV infection during
a 20-year period it was found that the overall rate of vertical
transmission was 37.1%, and ranged from 5.6% for pre-
conceptional progressively up to 64.1% for third trimester
infections [4]. In addition, primary infection in early gestation
carries the highest risk of symptomatic infection in the infected
fetuses and newborns [5,6].
The mechanisms of protection from vertical transmission
remain to be elucidated, although the role of T cells in controlling
HCMV infection is well established [7–10]. In addition to T cells,
antibodies may play a role in controlling vertical transmission. In
this respect, Nigro et al. reported that HCMV-specific hyper-
immunoglobulin preparations appeared to be effective in both
prevention of fetal infection and treatment of fetuses infected
in utero [11]. In addition, it was suggested that maternal antibodies
may enhance or prevent fetal infection according to their low or
high neutralizing activity [12].
The major targets of the neutralizing antibody response to
HCMV are the glycoproteins gB, gM/gN and gH/gL/gO, which
mediate entry into host cells [13]. However, we recently found that
human monoclonal antibodies neutralize HCMV infection by
targeting a protein complex that includes gene products of the
HCMV UL128-131 locus [14], which is known to be indispens-
able for virus growth in endothelial cells and virus transfer to
leukocytes [15]. These antibodies were found to be a thousand-
fold more potent in neutralizing virus infection of epithelial/
endothelial cells as compared to antibodies directed against gB.
The UL128-131 gene products are assembled with gH and gL to
form a 5-protein (pentamer) complex (gH/gL/pUL128-130-131),
which is an alternative to the classical gH/gL/gO complex [16].
Accordingly, the pentamer complex confers to HCMV the ability
to infect endothelial and epithelial cells as well as myeloid cells
[16–19]. Furthermore, gB and gH/gL, but not gH/gL/gO,
mediate entry into fibroblasts [20,21], while both gH/gL and gH/
gL/pUL128-131 are necessary for virus entry into epithelial and
endothelial cells [22].
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Following natural infection, the first wave of the humoral
response is characterized by antibodies able to neutralize the
infection of endothelial/epithelial cells, in contrast to antibodies
able to neutralize infection of fibroblasts [23]. By analyzing the
antibody response to the pentameric complex in primary HCMV
infections using cells transfected with multiple adenovirus vectors,
each carrying a single gene of the pentamer, we found that the IgG
antibody response to UL128-131 gene products is generally
superior to the response to gH and appeared to follow the
neutralizing antibody response [24]. These findings support the
hypothesis that the HCMV pentamer glycoprotein complex may
be an important target of neutralizing antibodies. In line with this
hypothesis is the observation that the Towne vaccine (lacking
a functional pentamer complex) and the gB/MF59 subunit
vaccine, both characterized by partial efficacy, induce an epithelial
entry-specific neutralizing activity that is on average 28-fold
(Towne) or 15-fold (gB/MF59) lower than that observed after
natural infection [25].
In the present study, we took advantage of new serological
assays, developed using human monoclonal antibodies (mAbs) and
soluble recombinant dimer and pentameric complexes [14,26], to
dissect the antibody response to HCMV glycoproteins in trans-
mitter and non-transmitter pregnant women. The results demon-
strate that in primary infections, the immune response to the
pentamer gH/gL/pUL128-131 complex is predominant, and that
the early presence of neutralizing antibodies directed to multiple
sites on the pentamer is associated with a reduced risk of HCMV
vertical transmission.
Materials and Methods
Ethics Statement
The study was approved by the Fondazione IRCCS Policlinico
San Matteo Bioethics Committee, and informed written consent
was obtained from each subject included in the study.
Patients
The antibody response to the HCMV glycoprotein complex
and its components was investigated in serum samples drawn
from: i) a group of 13 HCMV-seronegative healthy blood donors;
ii) a group of 20 HCMV-seropositive healthy blood donors; and iii)
a group of 46 subjects (43 pregnant women and 3 non-pregnant
subjects) with primary HCMV infection, in whom sequential
serum samples were drawn at periodic medical visits at the
Fondazione IRCCS Policlinico San Matteo, Pavia, Italy. Pregnant
women with primary infection were identified among women
referred to our Institution for suspected HCMV infection in
pregnancy by using a battery of tests, some of which were
commercially available and some developed in the laboratory. In
detail, HCMV-specific IgG and IgM were determined by ETI-
CYTOK-G and ETI-CYTOK-M (DiaSorin Saluggia, Italy),
respectively. Presence of virus-specific IgM was confirmed by an
in-house developed confirmatory ELA assay [27]. IgG avidity was
determined by an in-house developed ELISA test [28]. In
addition, neutralizing antibodies were routinely determined on
human embryonic fibroblasts as well as ARPE-19 epithelial cells
using the prototype HCMV strain VR 1814 [23]. HCMV in blood
of pregnant women was searched for by real-time PCR (detection
limit 25 copies/ml whole blood) and by pp65 antigenemia
determination on cytospin preparations of 26105 peripheral blood
leukocytes [29].
Primary HCMV infection was diagnosed based on the presence
of at least two of the following four criteria: HCMV-specific IgG
seroconversion, presence of virus-specificc IgM antibody, low IgG
avidity index (AI), and DNAemia [27–29]. Recently, quantitative
DNAemia results expressed as HCMV DNA copies/ml blood
were translated into IU/ml with reference to the WHO
International HCMV DNA Standard [30]. Timing of infection
onset was achieved in the great majority of women based on the
presence of a HCMV-specific seroconversion (within an interval of
1–2 months between the last seronegative and the first seropositive
serum sample) and/or other serologic (IgM antibody and IgG AI)
and virologic (DNAemia) findings, associated with presence of
clinical signs/symptoms. In the minority of women, in whom
signs/symptoms were not observed, IgG and IgM antibody
kinetics were considered in association with low IgG AI for
determination of infection onset timing [31].
HCMV transmission was diagnosed either antenatally by
detection of viral DNA in and virus isolation from amniotic fluid
samples or by virus isolation from urine samples collected within
the first 2 weeks of life.
Of the 43 pregnant women, 19 transmitted and 22 did not
transmit the infection to the fetus. Regarding the two remaining
women, for one, transmission was unknown due to pregnancy
termination, while the second had a delayed transmission to the
fetus (amniotic fluid was negative but the newborn was infected at
birth). Among the 43 pregnant women, 23 were selected (11 non-
transmitters, and 12 transmitters) for the study of serum antibody
titers against HCMV glycoprotein complexes and site-specific
reactivity, based on the availability of multiple sequential serum
samples, with the first available sample drawn within 60 days after
onset of infection and available data sufficient to estimate the date
of infection onset with a high probability. Timing of infection
onset was achieved in 21/23 of these women based on the
presence of clinical signs/symptoms associated to serologic data. In
the remaining 2 women, in whom signs/symptoms were not
observed, onset of infection was approximately assigned to a time
point in the middle of the 1-month interval between the first
positive and the last negative HCMV-specific IgG serum sample.
Preparation and Purification of gH/gL/pUL128-131, gH/
gL and gB
As previously reported, intronless, full-length UL128, UL130,
UL131, gH, gL, gO, and gB were cloned into pcDNA3 vectors
(Invitrogen) by PCR with Pfu turbo on cDNA of VR1814-infected
MRC-9 cells, using primers introducing the desired restriction sites
[14]. In order to obtain the secreted soluble forms of the
glycoproteins, the transmembrane portion and the cytoplasmic
domains were removed from gH and gB genes [16,32]. Then, the
gH/gL/pUL128-131 complex was obtained by co-transfecting the
cells with UL128, UL130, UL131, gL, and gH plasmids with
a mass ratio of 0.6:0.6:0.6:0.8: 1, while the gH/gL complex was
obtained by co-transfecting the cells with gH, gL and gO plasmids
with a mass ratio of 1: 1.2:0.8. For purification purposes 6x Histag
was added to the C-terminus of UL131, gH, and gB, for gH/gL/
pUL128-131, gH/gL and gB, respectively.
Constructs were used to transfect HEK293F cells (Invitrogen)
with DNA and polyethyleneimine MAX (Polysciences) premixed
in Opti-PRO SFM medium (Invitrogen). After 10 days culture the
supernatant was harvested, and the presence of the proper HCMV
glycoprotein complex was verified by ELISA using human mAbs
specific for the different neutralization sites of the complex [14].
Glycoprotein complexes were purified on Histrap HP columns
and subsequently on a Superdex 200 gel filtration column (GE
Healthcare) according to the manufacturer’s instructions. Recom-
binant gB, gH/gL and gH/gL/UL128-131 had apparent molec-
ular weights of 200–300 kDa. Fractions containing the protein of
interest were merged and concentrated using ultrafiltration 30K
Antibody Response to the gH/gL/pUL128-131 Complex
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columns (Sartorius Stedim Biotech, Goettingen, Germany). SDS-
PAGE and Western blot analysis of recombinant proteins
confirmed their identity and purity .80% (see Results).
Determination of IgG Antibodies to the Pentamer, gH/gL
and gB by ELISA
Half-area 96-well polystyrene plates (Corning) were coated
overnight with an in-house developed murine anti-gH mAb
(mH1P73), or an anti-gB mAb (HCMV37, Abcam, Cambridge,
UK) and blocked with 5% skimmed milk in PBS, as recently
reported [26]. After a double wash with PBS-0.05% Tween20,
ELISA plates were incubated for 90 min with cell culture
supernatants containing the pentamer, gH/gL complex or gB
released from transfected cells. Following two washings, human
serum (in 5% skimmed milk) was added at a single 1:50 dilution or
in serial two-fold dilutions and incubated 1 h at RT. After four
washings, the horseradish peroxidase-labeled goat IgG fraction to
human IgG (Fc-chain-specific) was added and incubated 45 min at
room temperature, prior to adding the substrate solution. Net OD
was obtained by subtracting the OD value obtained by incubating
the serum without antigen from the value given by the serum
incubated in the presence of antigen.
In order to equalize the amount of pentamer and gH/gL dimer
bound to the solid phase and assuming that the different
components of the pentamer were stoichiometrically represented
at a ratio of 1:1:1:1:1, the two preparations were tested in a capture
ELISA system and their dilutions were normalized in order to
obtain equal OD values when tested with an anti-gH primary
mAb. Subsequently, 23 HCMV-seronegative and 10 HCMV-
seropositive healthy blood donors were tested in a capture ELISA
system to establish a cut-off indicating the reactivity of human sera
with the pentamer or the dimer gH/gL. The mean value +2SD
gave a cut-off of 0.10 (OD) for both the pentamer and gH/gL and
a cut-off of 0.20 for gB antibodies.
Inhibition of mAb Binding (IMAB) by Competitive Human
Sera
The study of the reactivity of sequential human sera (from 11
non-transmitter and 12 transmitter pregnant women with primary
HCMV infection) with previously identified neutralization sites of
glycoproteins forming the pentamer complex was performed by
using a competitive binding assay [26,33]. In this assay, human
sera containing antibodies to a defined neutralization site
prevented binding of the relevant murinized site-specific mAb.
Briefly, following coating of a human mAb (anti-gH, 3G16) to the
solid-phase, and blocking of non-specific binding sites with 5%
skimmed milk in PBS, the complex was captured after a 90 min
incubation at RT. Human serum (or mAb) was added in serial
two-fold dilutions in duplicate (starting from 1:5) and incubated
1 h at RT, prior to adding a primary murinized mAb (at
a concentration corresponding to 80% of its maximal OD
reactivity) for 1 h at RT, and then a secondary alkaline
phosphatase-labeled goat anti-mouse IgG (c-chain-specific) for
45 min at RT and, finally, the substrate solution. The % inhibition
was calculated as follows: (OD w/o serum-OD w serum)/(OD w/
o serum-OD background)6100. To calculate the IMAB50 titer,
a dose-response curve plotting log10 serum dilution vs % inhibition
was constructed, from which the serum dilution corresponding to
the IMAB50 titer was interpolated. By using this curve, it was
possible to interpolate positivities between 1:1 (undiluted serum)
and 1:5 (first tested serum dilution).
Neutralization Assay
Serial dilutions of heat-inactivated human sera were incubated
in duplicate for 60 min at 37uC with an equal virus volume
containing 100 infectious units of VR1814 [23]. Virus-antibody
mixtures were then added in duplicate to monolayers of ARPE-19
or HELF cells, and centrifuged at 7006g for 30 min. After 48 h
incubation, cells were fixed and stained for HCMV p72 using
a pool of murine mAbs [34]. The serum dilution inhibiting virus
infectivity by 50% or more with respect to virus controls was
reported as the neutralizing-antibody titer.
Plaque Formation Inhibition (PFI) and Leukocyte Transfer
Inhibition (LTI) by Human mAbs and Sera
Using serial dilutions of human mAbs or human sera from
patients with primary HCMV infection, PFI in ARPE-19 cells as
well as LTI from HCMV-infected HUVEC was investigated, as
previously reported [23,26].
PFI was investigated as follows. Following virus absorption (50
pfu) by centrifugation for 30 min at 7006g at RT, 96-well
microplate cell cultures were washed and supplemented with
medium containing serial dilutions of mAbs or serum for 120 h.
Cells were then fixed and stained by using a p72-specific mAb pool
[34]. The percent PFI was determined by dividing the difference
between the number of viral plaques in the absence or presence of
mAb (or human serum) by the number of plaques in the absence of
antibody (6100). All experiments were done in triplicate.
LTI experiments were performed in 24-well microplates by
incubating human mAbs for 2 h at 37uC with monolayers of
VR1814-infected HUVEC (96 h pi) prior to and overnight during
co-cultivation with leukocytes [23,35]. After co-culture, leukocytes
were purified by migration through a Transwell device (Costar).
Control experiments were done in the absence of serum or mAbs.
Leukocytes were then fixed, permeabilized and stained with a pool
of pp65-specific murine mAbs, as reported [36]. The percent
inhibition was determined by dividing the difference between the
number of pp65-positive leukocytes in co-culture experiments
done in the absence or presence of antibody by the number in the
absence of antibody (6100).
To calculate PFI50 and LTI50 titers, a dose-response curve
plotting % inhibition vs mAb concentration (or serum dilution) was
constructed, from which the antibody dilution corresponding to
PFI50 or LTI50 titer was interpolated.
Statistical Analysis
Non-linear regression models were used to express the kinetics
of different serological parameters (IgG antibodies to gH/gL/
pUL128-131, gH/gL and gB; neutralizing antibodies and PFI50
titers). The curves were compared by the extra-sum-of square F
test (GraphPad Prism 5.0 software). The relative time to
appearance of sera reactivity to the different neutralization sites
was analyzed by the Kaplan-Meyer method and compared by the
log-rank test. IMAB50 titers to the different neutralization sites,
numbers of pentamer epitopes recognized and HCMV DNA load
were compared by the Mann-Whitney U-test, whereas the
proportion of patients with HCMV DNA in blood was compared
by the Fisher’s exact test. Linear regression was used to calculate
the correlation between log10 neutralizing and ELISA IgG
antibody titers.
Antibody Response to the gH/gL/pUL128-131 Complex
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Results
Production and Characterization of Soluble HCMV
Glycoprotein Complexes
To characterize patient response to HCMV glycoprotein
complexes, we produced recombinant soluble pentamer, dimer
and gB by transiently transfecting 293F HEK cells and purifying
his-tagged proteins from cell culture supernatants. SDS-PAGE
and Western blot analysis with specific antibodies confirmed the
identity of proteins recovered (Fig. 1).
Early Production of Pentamer-specific Antibodies that
Neutralize Epithelial Cell Infection
The kinetics of the antibody response to different HCMV
antigens and the serum capacity to neutralize infection of
fibroblasts or epithelial cells was investigated in 43 pregnant
women and 3 non-pregnant women during the first year after
onset of primary HCMV infection. Soluble forms of the gH/gL/
UL128-131 pentamer complex, gH/gL dimer and gB were
produced in transfected cells, and used to measure specific IgG
by ELISA in longitudinal serum samples (median number 5, range
3 to 9 sera/subject, n = 240 sera). As shown in Figure 2A,
antibodies to gB increased rapidly and to significantly higher levels
as compared to those against the pentamer, while antibodies to
gH/gL showed significantly slower kinetics. Serum antibodies
capable of neutralizing infection of an epithelial cell line (ARPE-
19) appeared early and rapidly reached high titers. In contrast,
serum antibodies capable of neutralizing infection of fibroblasts
(HELF) appeared later and peaked only at approximately 6
months after onset of infection, showing titers lower by 2–3 log10
(Fig. 2B). As total IgG antibodies to HCMV lysate increased,
HCMV DNA as well as IgM antibodies to HCMV lysate declined
in the first 3–6 months after infection (Fig. 2B).
We then investigated the existence of a correlation between
anti-pentamer ELISA-IgG antibodies and titers of serum anti-
bodies able to neutralize epithelial cell infection. As shown in
Fig. 2C, there was a good correlation between anti-pentamer
antibody levels and neutralizing titers in the first 2 months after
onset of infection, which was lost at later time points (.60 days)
after onset of infection.
To investigate the relative contribution of antibodies with
different specificities to viral neutralization, we absorbed penta-
mer-, gH/gL- or gB-specific antibodies from the sera of 3 patients
by adding the relevant purified antigens or influenza hemagglutin
(HA) as a control. Depletion was specific and efficient (greater than
90%) as shown by specific ELISA (Table 1). Strikingly, sera pre-
adsorbed with the pentameric complex showed a highly reduced
capacity (.90%) to neutralize viral infection of ARPE-19, even
when collected at late time points (184 or 406 days after onset of
infection), while their activity was substantially unaffected when
pre-adsorbed with gH/gL or gB (Fig. 2D). Taken together, these
data suggest that the neutralizing activity in sera of pregnant
women with primary HCMV infection is conferred by antibodies
against the pentameric gH/gL/pUL128-131 complex.
Kinetics of Serum Antibodies in Transmitter and Non-
transmitter Women
We next compared the kinetics of serum antibodies in 11
women who did not transmit the virus to the fetus (non-
transmitter) and 12 women who transmitted the virus (transmitter),
as reported in Table 2. In both groups of patients, IgG antibody
titers against gB increased rapidly with overlapping kinetics,
reaching a plateau within the first 30 days after infection (Fig.
S1A). In contrast, IgG antibodies to the gH/gL dimer and the
pentamer appeared earlier and reached higher titers in non-
transmitter women compared to transmitter women (Fig. S1B, C).
Accordingly, no significant differences in gB antibody titers in
transmitters and non-transmitters were observed when the data
were examined by grouping them in three time intervals (Fig. 3A),
while IgG antibody titers against the pentamer and the gH/gL
dimer were significantly higher in non-transmitter women
compared to transmitter women in the first 30 days after onset
of infection although, at later time points (31–60 days and .60
days), titers increased in both groups reaching comparable levels
(Fig. 3B, C). Interestingly, the number of HCMV DNA copies/ml
blood was significantly higher in transmitters as compared to non-
Figure 1. SDS-PAGE and Western blot (WB) analysis of soluble HCMV glycoprotein complexes. (A) Pentameric gH/gL/pUL128-131
complex, (B) gH/gL and (C) gB complexes were subjected to SDS-PAGE and Western blotting. Samples were stained with Coomassie blue (left panels)
or probed with specific antibodies after WB (right panels). (B) A band of about 60 kDa on gL blot is apparently a co-purified contaminant recognized
by anti-gL polyclonal serum raised in rabbits. (C) Soluble gB exists in full-length and truncated forms that associate in dimeric complex, as described
in Carlson et al. (32). N-terminus of truncated gB form is not detected since gB was his-tagged on the C-terminus and the blot was probed with anti-
histag antibody.
doi:10.1371/journal.pone.0059863.g001
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transmitters, both in the first (median 1,000 DNA copies/ml blood
vs undetectable) and second (median 42 DNA copies/ml blood vs
undetectable) time interval (#30 days and 31–60 days after onset),
whereas no difference was observed between the two groups in the
.60 day interval (Fig. 3D).
Taken together, these results indicate that non-transmitter
mothers are characterized by a more rapid IgG antibody response
to the pentameric complex and the gH/gL dimer and that this
early antibody response correlates with more rapid control of viral
infection.
Figure 2. Kinetics of the antibody response to primary HCMV infection. (A) Kinetics of the appearance of anti-pentamer (IgG-Pent), anti-gH/
gL (IgG-gH/gL) and anti-gB (IgG-gB) antibodies in 46 subjects with primary HCMV infection. Shown are individual values and non-linear regression
curves for the three specificities. P-values were calculated using the extra-sum-of square F test. (B) Kinetics of the mean HCMV serological response in
the 46 patients’ sera. IgG-HCMV refers to HCMV lysate-specific IgG Arbitrary Units (AU); IgM-HCMV refers to HCMV lysate-specific IgM ratio; Nt-HELF
and Nt-ARPE19 refer to neutralizing antibody (Neut Ab) titer on human embryonic lung fibroblasts (HELF) and epithelial (ARPE-19) cells, respectively;
HCMV DNA refers to viral load in blood. (C) Correlation between IgG-pentamer antibody titers measured by ELISA and neutralizing antibody titers
measured using ARPE-19. Values were obtained from sera collected ,60 day post infection (filled diamonds) or .60 days post infection (empty
diamonds). The regression coefficient (r2) is also shown. (D) Neutralizing antibody (Neut Ab) titers of sera from 3 patients (Pt.A, Pt.B, and Pt.C) were
measured using ARPE-19. Sera were used either untreated or after absorption with the soluble pentameric complex, gH/gL dimer, or gB proteins from
HCMV or with influenza A virus hemagglutinin (HA).
doi:10.1371/journal.pone.0059863.g002
Table 1. Effect of serum absorption with purified HCMV proteins on ELISA IgG antibody titer.
ELISA IgG Ab titer to ELISA titer (% depletion) following absorption with purified
pentamer gH/gL gB HAa
pentamer (1:3,200) 1:50 (99) 1:800 (75) 1:3,200 (0) 1:3,200 (0)
gH/gL (1:1,600) 1:100 (94) 1:100 (94) 1:1,600 (0) 1:1,600 (0)
gB (1:12,800) 1:12,800 (0) 1:12,800 (0) 1:800 (94) 1:12,800 (0)
aInfluenza A hemagglutinin.
doi:10.1371/journal.pone.0059863.t001
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Distinct Kinetics of Antibody Responses to 10
Neutralization Sites of the Pentamer in Non-transmitter
and Transmitter Women
We have previously isolated from human memory B cells a panel
of neutralizing monoclonal antibodies that target distinct sites on
the pentameric complex [14]. To analyze the fine-specificity of the
serum anti-pentamer antibodies in transmitter and non-trans-
mitter mothers, we measured the capacity of the sera to inhibit
binding of the monoclonal antibody panel to plate-bound
pentamer (Fig. S2). Using the IMAB assay, we were able to
define the serum titers of antibodies to 10 different sites: site 1
(defined by mAb 15D8 that binds to pUL128); sites 2, 3 and 4
(defined by human mAbs 1F11, 4N10, and 10P3 that bind to three
non-overlapping epitopes of the dimer pUL130-131); sites 5 and 6
(defined by human mAbs 6G4, and 7I13 that bind to the trimer
pUL128-130-131); site 7 (defined by human mAb 8I21 that
recognizes an epitope shared by gH/gL/UL128-130); sites 8, 9,
and 10 (defined by human mAbs 3G16, 11B12, and H1P73 that
recognize non-overlapping epitopes on gH). The specificity of the
assay was demonstrated by lack of IMAB reactivity of an irrelevant
mAb (specific for HA) and by the fact that none of the HCMV-
seronegative blood donors tested showed reactivity with any of the
neutralization sites studied, while all of the HCMV-seropositive
blood donors with remote HCMV infection showed reactivity with
each of the 10 neutralization sites tested.
The IMAB assay was performed on serum samples from 23
pregnant women (11 non-transmitters, and 12 transmitters). When
the cumulative kinetics of the antibody response to all neutrali-
zation sites was examined, it was found that the antibody response
to pUL128 (site 1) appeared significantly earlier (P,0.01) than
those to the other pentamer antigenic sites, whereas antibodies to
site 4 (anti-pUL130-131), and sites 9 and 10 (anti-gH) were
detected significantly later (P,0.05) as compared to antibodies to
sites 2, 3, and 5 to 8 (Fig. 4). These findings highlight an individual
difference in the production of antibodies to the different sites of
the pentameric complex.
We next compared the IMAB50 titers for the 10 antigenic sites
in the two groups of transmitter and non-transmitter women
examined according to the three time intervals (#30, 31–60, .60
days after onset, Fig. 5). Serum samples were available for 8
transmitter and 8 non-transmitter women in the first time interval,
and for 12 transmitter and 11 non-transmitter women at the other
time intervals analyzed. In blood samples collected during the
second month after the onset of infection (median sampling time
47, range 31–60, days for NT women vs 46, range 31–60, days for
T women) the IMAB50 titer was significantly lower in the group of
transmitters as compared to the group of non-transmitters for most
of the sites investigated (except for sites 1, 8 and 10). In addition,
IMAB50 titers to site 1 were significantly higher in non-
transmitters in the#30 days time interval (Fig. 5A), and antibodies
to site 7 (Fig. 5G) remained significantly higher in this group also
at the late time point examined (.60 days), when reactivity to the
other sites was no longer different between the two groups. In
order to exclude a possible bias due to different criteria used for
timing, we repeated the analysis after exclusion of the two patients
in whom the onset infection was dated on the basis of serologic
data only (IgG seroconversion) in the absence of symptoms, in
order to exclude a possible bias due to different criteria used for
timing. Except for site 6, the IMAB50 titers to the other sites
remained significantly lower in sera from T women (data not
shown).
The Breadth of Anti-pentamer Antibodies is Associated
with Reduced Rate of Intrauterine Transmission
We next compared the breadth of the anti-pentamer response in
non-transmitter and transmitter women and whether there was an
association with control of viral infection. As shown in Fig. 6A, C,
the number of neutralization sites recognized by transmitter
women was significantly lower than the number of sites recognized
by non-transmitter women during both the first and second month
after onset of infection, while no differences were found in the.60
day interval (Fig. 6E). Furthermore, the number of women positive
for HCMV DNA in blood was higher among transmitter women
as compared to non-transmitter women, both in the first (positive
women 8/8 among transmitter vs 4/8 among non-transmitter
women, P= 0.07) and second (positive women 9/12 among
transmitter vs 3/11 among non-transmitter women, P= 0.04)
month after onset (Fig. 6B, D). No difference (positive women 1/
12 among transmitter vs 1/11 among non-transmitter women,
P= ns) was observed between the two groups in the .60 day
interval (Fig. 6F).
Table 2. Characteristics of the 23 pregnant women analyzed for antibodies against neutralization sites in the pentameric complex.
Parameter
Non-transmitter mothers
(n=11) Transmitter mothers (n =12) P
Gestational week at onset of infection, median (range) 10 (6–16) 7 (4–26) nsa
No. symptomatic infection (%) 9 (82) 12 (100) nsa
No. samples available, median (range) 5 (3–9) 6 (4–8) nsa
Serologic parameters utilized for dating infection onset, no. cases (%)
-Seroconversion 5 (45) 7 (58) nsb
-IgM kinetics 5 (45) 4 (33) nsb
-IgG avidity kinetics 4 (36) 2 (17) nsb
Median time to HCMV DNAemia clearance from blood (days) 32 93 ,0.01c
No. pregnancy terminations (%) 1 (9)d 1 (8) nsb
aMann-Whitney U test.
bFisher’s exact test.
cLog-rank test.
dTermination of pregnancy due to severe fetal malformations not related to HCMV infection.
doi:10.1371/journal.pone.0059863.t002
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Blocking of Viral Spread and Transfer to Leukocytes by
Neutralizing Human mAbs and Human Sera
Lastly, we tested mAbs of defined specificity and serum samples
from transmitter and non-transmitter women for their capacity to
inhibit cell-to-cell spread (PFI50) of HCMV in ARPE-19 cell
monolayers.
Consistently, mAbs directed against the pentamer showed
greater inhibition in comparison with antibodies directed against
gH or gB (Fig. 7A). Conversely, only antibodies against gB or gH
blocked virus spread in HELF cells, in the absence of any
significant blocking effect by antibodies directed to the pentamer
or UL128-131 gene products (data not shown). We also
investigated in vitro the inhibitory effect of human mAbs on the
transfer of virus from HUVEC to leukocytes (LTI50) [23]. We
found that, within the concentration range of 100 to 0.1 mg/ml,
most neutralizing antibodies displayed significant blocking of virus
transfer to leukocytes in the range of 100% (100 mg/ml) to 70%
(0.1 mg/ml). This blocking effect was characteristic of antibodies
that bind exclusively to the pentamer, but not of antibodies that
bind to gH/gL or gB (Fig. 7B). A similar PFI effect was observed in
sequential sera from 5 transmitter and 4 non-transmitter women
with primary HCMV infection (Fig. 7C). The PFI50 was
significantly higher in non-transmitter women during the first
month after onset and close to significance (P= 0.06) in the second
month after onset (Fig. 7D). Similarly, the average kinetics of the
PFI50 titer in non-transmitter women increased significantly faster
and reached a higher level as compared to transmitter women
(Fig. 7E).
Taken together, these findings indicate that the neutralizing
activity of both human mAbs and human sera is able to inhibit
both cell-to-cell spread and virus transfer to leukocytes, thus
inhibiting virus dissemination by two different mechanisms.
Discussion
In this study, we report that early detection of HCMV
neutralizing antibodies directed against the pentameric complex
gH/gL/pUL128-131 and, in particular, to the UL128-131 gene
products appears to be associated with a lower rate of HCMV
transmission from the mother to the fetus. This was shown by the
finding that non-transmitter mothers exhibit an earlier antibody
response to different antigenic sites of the pentamer as compared
to transmitter mothers. The biological relevance of anti-pentamer
antibodies is in parallel highlighted by the finding that antibodies
to gB are produced by non-transmitter and transmitter mothers
with the same kinetics and in comparable amounts. This latter
aspect also excludes any systematic error in determining the time
of infection that might have biased our sampling.
The important role of antibodies directed against UL128-131
locus gene products is also supported by the following findings: i)
the absorption of sera with recombinant soluble pentamer strongly
reduced serum neutralizing activity, while absorption with gH/gL
or gB had minimal effects, consistent with data obtained using
hyper-immune globulin preparations [37]; ii) mAbs targeting the
pUL128-131 components of the pentamer showed a thousand-fold
greater neutralizing activity as compared to mAbs specific for gH
or gB [14]; iii) anti-pentamer antibodies potently inhibit infection
of epithelial, endothelial and myeloid cells, thus interfering with
viral spread in vivo and potential virus transmission to the placenta
and the fetus, and iv) during the first two months after onset of
infection there was a significant correlation between the titers of
serum IgG antibodies to the pentamer and neutralizing titers
determined in epithelial cells. The reduced correlation observed in
the subsequent period may be due to the appearance of pentamer-
specific antibodies without neutralizing activity, as well as to the
appearance of neutralizing antibodies with different specificity. On
the other hand, the lack of correlation between gB-specific
antibodies and control of HCMV transmission to the fetus may
Figure 3. IgG antibody titers and DNA viral load at three time points of primary HCMV infection. IgG antibody titers in 11 non-
transmitter (NT) and 12 transmitter (T) mothers against gB (A), gH/gL (B), or pentamer (C) at three different time intervals (#30 days, 30–60 days,.60
days) after onset of infection. (D) HCMV DNA copies/ml blood in the same sera samples at the three time intervals. Dotted lines represent the
detection limit of the assays. P-values were calculated using the Mann-Whitney U-test (A-C) or the Fisher’s exact test (D).
doi:10.1371/journal.pone.0059863.g003
Figure 4. Cumulative antibody response to the pentamer neutralization sites. Patients’ antibody response to neutralizing sites of the
pentamer estimated via inhibition of monoclonal antibody binding (IMAB) assay using a panel of 10 human monoclonal antibodies with defined
specificity for different sites on the HCMV pentamer complex, as indicated. The cumulative incidence of site-specific antibodies in 23 pregnant
women with primary HCMV infection during the entire follow-up period is shown.
doi:10.1371/journal.pone.0059863.g004
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be due to the fact that the great majority of antibodies elicited by
gB do not neutralize HCMV infection [38], whereas we have
evidence that most human pentamer-specific antibodies are
neutralizing (A Kabanova, unpublished data).
Conventional ELISA measurement of sera reactivity with crude
viral antigens does not discriminate between antibodies playing
a primary role in antiviral immunity (i.e. those recognizing
neutralization sites) and antibodies reactive with non-functional
sites. In this study, we used the IMAB assay that allowed us to
Figure 5. IMAB50 titers by site-specific antibodies present in human sera from primary HCMV infection. IMAB50 titers of neutralizing
site-specific IgG antibodies in 12 transmitter (T) and 11 non-transmitter (NT) mothers at three different time intervals (#30 days, 30–60 days, .60
days) after onset of infection. (A-J): Sites 1 to 10 as defined by the indicated human monoclonal antibodies to gH/gL/pUL128-130-131 [14]. Dotted
lines represent the detection limit of the assays. P-values were calculated using the Mann-Whitney U-test; n.d., not detected.
doi:10.1371/journal.pone.0059863.g005
Figure 6. Overall number of neutralization sites of the pentamer reactive with human sera and viral load at three time points.
Number of neutralization sites recognized by sera from 11 non-transmitter (NT) and 12 transmitter (T) mothers at (A) less than 30 days, (C) 31–60 days,
and (E) more than 60 days after onset of infection. (B, D, F): Number of HCMV-DNA positive (black bars) and HCMV-DNA negative (white bars) women
in the NT and T groups at the same time intervals. P-values were calculated using the Mann-Whitney U-test (A, C, E) or the Fisher’s exact test (B, D, F).
doi:10.1371/journal.pone.0059863.g006
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study the kinetics of antibodies directed against 10 neutralization
sites on the pentameric complex that were previously identified by
a panel of human mAbs [14]. This site-specific analysis revealed
that in non-transmitter mothers antibodies targeting 8 out of 10
sites appeared with faster kinetics compared to transmitter
mothers. Thus, the IMAB assay appears efficacious in revealing
differential kinetics of site-specific neutralizing antibodies in the
two groups of mothers in the early phase after onset of infection,
thus representing a useful diagnostic parameter.
Neutralizing antibodies are thought to act primarily by
preventing cell-free virus from infecting susceptible cells. However,
the main route of HCMV dissemination in vivo is associated with
viral spread by infected polymorphonuclear leukocytes and
monocytes [39]. Here, we have shown that mAbs to the pentamer
sites as well as sera containing such antibodies effectively inhibited
viral spread as measured by plaque formation [23]. Importantly,
the capacity of serum to inhibit viral spread was significantly lower
in transmitter as compared to non-transmitter women. An
additional correlate of potential in vivo protection was studied by
Figure 7. Plaque formation and leukocyte transfer inhibition by humanmonoclonal and serum antibodies. Dose-effect inhibition of (A)
HCMV plaque formation (PFI) in ARPE-19 cells, and (B) HCMV transfer to leukocytes (LTI) from infected HUVEC cells by serial concentrations of human
mAbs specific for different sites on the pentamer complex. An anti-gB mAb (7H3) was used as a control. (A) mAbs to gB and gH show a PFI50 activity
at a concentration about a thousand-fold higher in comparison to human mAbs directed to pUL128-131. (B) Comparable LTI50 activity was displayed
by human mAbs directed to pUL128-131, whereas mAbs to gH and gB again show a much weaker inhibitory effect. (C) Individual PFI50 titers in
sequential sera collected within the first 3 months after onset of infection in 5 transmitter (T) and 4 non-transmitter (NT) pregnant women. (D) PFI50
titers at three different time intervals (#30 days, 30–60 days, .60 days) after onset of infection are shown. P-values were calculated using the Mann-
Whitney U-test. (E) Regression curves of PFI50 titers in transmitter (T) and non-transmitter (NT) women. P-value was calculated using the extra-sum-of
square F test.
doi:10.1371/journal.pone.0059863.g007
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investigating the LTI50 activity (i.e. blocking HCMV transfer from
endothelial cells to leukocytes) of human mAbs. In this case, all
mAbs directed to the pentamer complex were able to block
transfer from HUVEC to leukocytes. Thus, the pUL128-131 gene
products appear to be involved in the mechanism of virus transfer
to leukocytes and virus dissemination [39].
The delayed development in transmitter women of HCMV-
specific T-cells with proliferative potential and the TEMRA
phenotype have been identified as two other risk factors predictive
of virus transmission from mothers to fetus during pregnancy (7–
10). During primary HCMV infection, the appearance in
peripheral blood of T cells able to proliferate in vitro in response
to a recall HCMV stimulus, as well as the development of TEMRA
cells were found to correlate with clearance of virus from blood
[8,9,40]. Thus, it can be hypothesized that early development of
antibodies to the neutralization sites of the pentamer complex,
along with functional T cell response, synergistically induce a more
rapid block of HCMV dissemination resulting in faster clearance
of virus from blood. Alternatively, it could be hypothesized that
a lower viral load after infection may determine both lack of
transmission to the fetus and a faster immune response in the
mother. However, it is more likely that the maternal immune
response is responsible for the control of viral replication and
dissemination and not vice versa.
Administration of human hyperimmune globulin (Ig) in
pregnant women with primary HCMV infection has been claimed
as useful for both prevention and therapy of congenital HCMV
infection [11]. This treatment has also been reported to ameliorate
placenta oxygenation and nutrition [41] and to be beneficial in
decreasing the severity of disabilities caused by fetal HCMV
infection after primary maternal infection during pregnancy [42].
In the present study, the major differences in antibodies reactive
with the neutralization sites of the pentamer were detected
between 30 and 60 days after onset of infection, whereas from 60
days onward the immunological parameters investigated were
comparable between transmitter and non-transmitter women.
These findings suggest that in pregnant women passive immuni-
zation (either by human Ig or human mAbs) might have an effect
in the prevention of congenital HCMV infection, when admin-
istered in an early phase after infection or prophylactically in
seronegative pregnant women.
In conclusion, the finding that an earlier antibody response to
the neutralizing sites of the pentamer in non-transmitter mothers
was associated with a reduced rate of HCMV vertical transmission
indicates that human anti-pentamer neutralizing mAbs could be
used for passive immunization of pregnant HCMV-seronegative
women and that the HCMV pentamer complex is a favourable
candidate for the development of an effective vaccine against
HCMV.
Supporting Information
Figure S1 Kinetics of IgG antibodies to glycoprotein
complexes. (A-C). Kinetics of appearance of anti-gB (A), anti-
gH/gL (B) and anti-pentamer (C) IgG antibodies in 11 transmitter
(T, black symbols) and 12 non-transmitter (NT, white symbols)
mothers. Individual values and non-linear regression curves in the
two groups of patients are shown. P-value was calculated using the
extra-sum-of square F test.
(TIF)
Figure S2 Determination of IMAB50 titer on sequential
sera from primary HCMV infection. Inhibition of a human
mAb anti-pUL128-131 (10P3, site 4-specific) binding by three
sequential human sera collected from a pregnant woman with
primary HCMV infection at different time points post-infection.
(TIF)
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